FSS icon
  • WHY FSS?
    • About Us
    • Careers
  • SERVICES
    • Data Management
    • Biostatistics
    • Quality
    • Monitoring
  • OUTREACH
    • Patient
    • STEM
    • Inclusivity and Sustainability
    • Community
  • RESOURCES
    • FSS News
    • Case Studies
    • Projects
    • Publications
  • CONTACT US
The APHINITY Trial: Results of the Primary Analysis

The APHINITY Trial: Results of the Primary Analysis

by Dewi Owens | Jul 13, 2017 | APHINITY, Publications

OVERVIEW Results from the APHINITY trial showed that in patients with HER2-positive metastatic breast cancer, pertuzumab added to trastuzumab and docetaxel has been shown to significantly prolong both progression-free survival and overall survival. The APHINITY Trial...
The NordICC Study: Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial.

The NordICC Study: Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial.

by Dewi Owens | Jul 1, 2016 | NordICC, Publications

OVERVIEW Although some countries have implemented widespread colonoscopy screening, most European countries have not introduced it because of uncertainty regarding participation rates, procedure-related pain and discomfort, endoscopist performance, and effectiveness....
The HERA Trial: Cardiac Events at 8 years median follow-up

The HERA Trial: Cardiac Events at 8 years median follow-up

by Dewi Owens | Jul 10, 2014 | HERA, Publications

TITLE OF PUBLICATION Trastuzumab-associated cardiac events at 8 years of median follow-up in the HERceptin Adjuvant Trial (HERA BIG 1-01) AUTHORS Evandro de Azambuja, Marion J. Procter, Dirk J. van Veldhuisen, Dominique Agbor-Tarh, Otto Metzger-Filho, Jutta...
The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer

The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer

by Dewi Owens | Feb 18, 2012 | NeoALTTO, Publications

OVERVIEW An argument that the two anti-HER2 agents, trastuzumab and lapatinib, given together would be better than single-agent therapy. STUDY DETAILS The Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study is a randomised, multicenter...
The HERA Trial: Cardiac Events at 8 years median follow-up

The HERA Trial: The Benefits of Trastuzumab by Degree of HER2 amplification

by Dewi Owens | Jun 20, 2009 | HERA, Publications

TITLE OF PUBLICATION Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial AUTHORS Mitch Dowsett, Marion Procter, Worta McCaskill-Stevens, Evandro de...
« Older Entries
Next Entries »

Recent Posts

  • FLAIR | British Journal of Haematology
  • COLONIZE | Annals of Internal Medicine
  • APHINITY | European Journal of Cancer
  • Navigating the biopharma services landscape
  • ALEXANDRA | Journal of the American Medical Association (JAMA)

Recent Comments

No comments to show.


Data Protection

EU Representative

Privacy

Cookies

CONTACT US
LinkedIn Logo

Frontier Science (Scotland) Ltd © 2022
Scottish Charity: SCO33112 | Scottish Company: SC220936

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}